Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Low bond yields and interest rates are often credited with supporting higher prices in the stock market. That's because lower bond yields can make the potentially higher yields offered by stocks ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of ...

Jones Financial Companies Lllp raised its stake in Sanofi (NASDAQ:SNY – Free Report) by 55.0% during the 4th quarter, ...

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year. Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related ...

Berenberg analyst Luisa Hector raised the firm’s price target on Sanofi (SNY) to EUR 120 from EUR 115 and keeps a Buy rating on the ...

With an average analyst rating of buy, Sanofi is clearly an analyst favorite. But the analysts could be wrong. Is SNY ...

In this article, we are going to take a look at where Sanofi (NASDAQ:SNY) stands against other best immunology stocks to buy now. Immunology is a rapidly advancing field with significant potential ...

The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the ... points (see more details here). Sanofi (NASDAQ:SNY) stands seventh ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where Sanofi (NASDAQ:SNY) stands against other best immunology stocks to buy now.

Sanofi India share price gains were likely driven by its quarterly results performance and the dividend announcements, even though stock gave away most gains as the stock market crashed and Sensex ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my post earnings update for NVAX stock.